Researchers from the University of Oxford have presented data from a Phase ll trial of AXA1125 for the treatment of long Covid fatigue.
The Phase ll randomised double-blind placebo-controlled trial evaluated the efficacy of AXA1125, an investigational treatment developed by US-based Axcella Therapeutics to treat the targeted patients.
Results showed that patients treated with AXA1125 experienced less fatigue than those who received a placebo.
Half of the 41 patients of the trial received twice daily dose of AXA1125, which is an orange-flavoured powder dissolved in water, for four weeks, and the remaining half received a placebo.
On average, patients had fatigue symptoms for nearly 18 months before joining the trial.
All the participants of the trial finished the study, with no serious adverse effects of both treatment or placebo reported during the trial.
Researchers of the trial monitored mitochondrial health in the muscles of the patients before and after taking the medication.
They used advanced magnetic resonance spectroscopy scans of the patients’ calf muscles when they bent and straightened their leg against the mild resistance from an exercise band to monitor mitochondrial health.
The scans revealed no overall difference between the patients treated with AXA1125 against the placebo.
Oxford University Radcliffe Department of Medicine associate professor and principal investigator of the trial Betty Raman said: “The reduction in patients’ own reports of fatigue is really positive news, and we hope that further work will help us understand the underlying processes behind this improvement too.
“There is still some way to go in treating all patients with long Covid – our results focus specifically on fatigue, rather than the breathlessness and cardiovascular issues that other long Covid patients have reported.”